Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Frank

Family Medicine Oklahoma City, OK Medical Doctor

NPI 1164450573 CMS profile 1136727

5721 Nw 132Nd St, Oklahoma City, OK 73142

Open in the dashboard

General payments

$3,090,489

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Frank of Oklahoma City, OK is reported in the CMS Open Payments database as having received $3,090,489 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $234 2
2024 General $3,082,225 1
2023 General $570 18
2022 General $915 36
2021 General $539 24
2020 General $630 36
2019 General $5,376 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Frank
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Alexander Frank were reported at $234. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Alexander Frank Family Medicine median Middle half National median
2019 $5,376 $150 $41–$543 $163
2020 $630 $120 $32–$415 $114
2021 $539 $137 $35–$551 $132
2022 $915 $137 $37–$512 $149
2023 $570 $149 $42–$545 $160
2024 $3,082,225 $156 $44–$560 $164
2025 $234 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Skye Orthobiologics LLC $3,082,225 1 payment
  2. Janssen Pharmaceuticals, Inc $4,469 15 payments
  3. ACADIA Pharmaceuticals Inc $1,157 24 payments
  4. Avanir Pharmaceuticals, Inc. $684 83 payments
  5. ITI, Inc. $552 33 payments
  6. Novartis Pharmaceuticals Corporation $258 15 payments
  7. Corium, Inc. $187 5 payments
  8. Gilead Sciences, Inc. $164 7 payments
  9. Neurocrine Biosciences, Inc. $136 1 payment
  10. Sun Pharmaceutical Industries Inc. $129 2 payments
  11. Other $528 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Debt forgiveness $3,082,225 1 payment
  2. Food and Beverage $4,020 213 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,560 2 payments
  4. Travel and Lodging $684 1 payment
Products named General payments · program years 2019–2025
  1. XARELTO $4,425 8 payments
  2. NUPLAZID Parkinsons Disease Psychosis $812 13 payments
  3. NUEDEXTA $684 83 payments
  4. CAPLYTA $552 33 payments
  5. NUPLAZID Parkinsons Disease Psychosis $345 11 payments
  6. ENTRESTO $258 15 payments
  7. INGREZZA $136 1 payment
  8. ADLARITY $119 3 payments
  9. DRIZALMA SPRINKLE $110 1 payment
  10. KAPSPARGO $110 1 payment
  11. Other $913 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 322 drugs

Part D claims

41,110

Median for Family Practice: 1,826

Drug cost

$3,276,359

Median for Family Practice: $120,094

Branded share of claims

19.7%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,067 $374,463
Invega Sustenna Paliperidone Palmitate Brand 87 $264,237
Vraylar Cariprazine Hcl Brand 264 $263,372
Aristada Aripiprazole Lauroxil Brand 57 $180,362
Trulicity Dulaglutide Brand 125 $115,200
Nuedexta Dextromethorphan Hbr/Quinidine Brand 119 $92,781
Abilify Maintena Aripiprazole Brand 30 $90,611
Rexulti Brexpiprazole Brand 61 $76,098
Cibinqo Abrocitinib Brand 12 $68,168
Januvia Sitagliptin Phosphate Brand 206 $66,401

The 10 drugs with the highest cost, of 322 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$207,303

Medicare's payments for the services billed

Medicare patients

464

Average age 76

Services billed

3,140

286 women, 178 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 66%
Alzheimer's or dementia 58%
Arthritis 49%
Diabetes 37%
Ischemic heart disease 34%
Heart failure 33%
Chronic kidney disease 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record